VJOncology Podcast

Latest Episodes:

The evolving role of nurses amidst global pandemic: perspectives, and highlights from cancer nursing leaders Apr 22, 2022

Show notes

In a world that is still acclimatizing to the COVID-19 pandemic, the fragility of many aspects of our society has been laid bare. Global health care systems were among the most seriously affected by the SARS-CoV-2 which has put a spotlight on the integral role of nurses not only in day-to-day patient care and running of healthcare facilities but also in public education and awareness campaigns, public health policymaking, and population-based medicine.

In this podcast, we hear from two oncology nursing leaders at the International Conference on Cancer nursing 2022 (ICCN), which took place virtually this year. Patsy Yates, AM, PhD, RN, FACN, FAAN, Queensland University of Technology, Brisbane, Australia, speaks on challenges experienced during the pandemic and positive initiatives that have arisen as a result. Stella Aguinaga Bialous, RN, DrPH, FAAN, University of California San Francisco School of Nursing, San Francisco, CA, advocates for the nursing community to embrace their influence on public health policy. We also catch up with Sarah Hargreaves, PhD, University of Sheffield, Sheffield, UK, who discusses findings from a survey on the impact of COVID-19 on lung cancer and mesothelioma nurses during the British Thoracic Oncology Group (BTOG) Conference 2022.

The post The evolving role of nurses amidst global pandemic: perspectives, and highlights from cancer nursing leaders appeared first on VJOncology.

The GU Cancer Sessions: Prostate & kidney cancer at ASCO GU 2022 Apr 11, 2022

Show notes

In this podcast, we hear from genitourinary (GU) cancer experts Tian Zhang, MD, Duke Cancer Center, Durham, NC, and Scott Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York City, NY, as they discuss some of their highlights in prostate and kidney cancer research presented at the 2022 ASCO GU Cancers Symposium, held in San Francisco, CA.

Listen to learn about the latest clinical research and practice-changing advances in GU cancers, including results from the Phase III PROpel and MAGNITUDE trials evaluating PARP inhibitors in patients with metastatic prostate cancer, as well the Phase III ARASENS trial studying darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel.

In renal cell carcinoma (RCC), the panel also discuss data from a Phase I/II trial evaluating axitinib in combination with nivolumab, the study of neoadjuvant avelumab and axitinib in localized clear-cell RCC in the Phase II NEOAVAX trial, as well as adjuvant pembrolizumab monotherapy in KEYNOTE-564.

The post The GU Cancer Sessions: Prostate & kidney cancer at ASCO GU 2022 appeared first on VJOncology.

Lung Cancer Screening: Current state and future directions Apr 01, 2022

Show notes

Lung cancer is one of the most common cancers in the world, and has a very low survival rate, partly due to many patients being diagnosed only once their disease has reached an advanced stage. Screening programmes for high-risk populations are a possible solution to this problem, as it would help to identify more lung cancer cases when they are in early stages, and are therefore more treatable.

In this podcast, we explain the current guidelines from the US, UK, and Europe, talk on key trials in lung cancer screening, and hear from leading experts about possible future screening methods.

The post Lung Cancer Screening: Current state and future directions appeared first on VJOncology.

Novel treatment approaches in HR+/HER2- breast cancer Mar 25, 2022

Show notes

Resistance to endocrine therapy in patients with hormone-receptor positive (HR+), HER2-negative breast cancer inevitably results in relapse and metastasis, leading to death. Understanding mechanisms of intrinsic and acquired resistance has been the focus of many clinical studies. Recent advances including the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and phosphoinositide 3-kinase (PI3K) inhibitors have improved progression-free survival and overall survival in these patients, however, endocrine resistance still develops in some patients. New classes of agents including oral selective estrogen receptor degraders (SERDs) and CDK7 inhibition have been explored in advanced HR+/HER2- metastatic breast cancer.

In this podcast, we hear from Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, Mario Campone, MD, PhD, Cancérologie de l’Ouest, René Gauducheau, St Herblain, France, and Charles Coombes, MD, PhD, Imperial College London, London, UK, as they discuss the latest data evaluating oral SERDs, elcacestrant and amcenestrant, as well as the CDK7 inhibitor, samuraciclib.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post Novel treatment approaches in HR+/HER2- breast cancer appeared first on VJOncology.

New treatment approaches for advanced or metastatic urothelial carcinoma Mar 18, 2022

Show notes

Clinical trials presented at the the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022 have been investigating treatment options for patients with advanced or metastatic UC who are ineligible for or have progressed on platinum-based chemotherapy, in hopes of improving patient prognosis. The LEAP-011 trial explored the addition of the VEGFR inhibitor, lenvatinib, to first-line pembrolizumab for patients ineligible for platinum-based chemotherapy, in hopes of increasing responsiveness to pembrolizumab. The TROPHY-U-01 trial investigated treatment with sacituzumab govitecan for patients with mUC who had progressed on platinum-based chemotherapy and ICIs. The ATLANTIS trial is exploring personalized maintenance treatment options for patients undergoing palliative chemotherapy in biomarker-defined subgroups of patients with advanced UC.

In this podcast, Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and the University of Paris-Saclay, Gif-sur-Yvette, France, Petros Grivas, MD, PhD, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA and Simon Crabb, PhD, MBBS, Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK, outline results from these clinical trials.

The post New treatment approaches for advanced or metastatic urothelial carcinoma appeared first on VJOncology.

The Breast Cancer Sessions: Highlights from SABCS 2021 Mar 11, 2022

Show notes

The San Antonio Breast Cancer Symposium (SABCS) 2021 saw ground-breaking data and developments in breast cancer being presented and in this special podcast, leading breast cancer experts Hope Rugo (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA) and Dave Cescon (Princess Margaret Cancer Center, Toronto, Canada), dissect the latest advances in the field and offer their unique perspectives.

Listen to this insightful roundtable discussion to learn about the latest clinical trial data in breast cancer, including pivotal developments from the KEYNOTE-522 and KEYNOTE-355 trials, which assessed pembrolizumab in triple-negative breast cancer. Developments in antibody-drug conjugates (ADCs) and the role of oral selective estrogen receptor degraders (SERDs) including elacestrant, following findings from EMERALD trial, are additionally examined.

The post The Breast Cancer Sessions: Highlights from SABCS 2021 appeared first on VJOncology.

The GI Cancer Sessions: Highlights from ASCO GI 2022 Mar 04, 2022

Show notes

In this episode of the VJOncology podcast, a panel of leading gastrointestinal (GI) cancer experts offer their perspectives on the key GI cancer data presented at the 2022 ASCO GI Cancers Symposium, held in San Francisco, CA, in January 2022.

In this podcast, Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI, is joined by Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, and Kristen Ciombor, MD, MSci, Vanderbilt University Medical Center, Nashville, TN.

Listen to learn about the latest clinical research and practice-changing advances in GI cancers, including the evaluation of durvalumab plus GemCis in biliary tract cancer in the TOPAZ-1 trial, how the HIMALAYA study compares to IMbrave150 in hepatocellular carcinoma and the assessment of adagrasib in KRAS G12C-mutated pancreatic ductal adenocarcinoma in KRYSTAL-1. In addition, the panel will be considering the implementation of circulating tumor DNA (ctDNA) testing in clinical practice for GI cancers following recent results from the CIRCULATE-Japan study, how the ACCENT IDEA study could change practice in stage III colorectal cancer, as well as advances in PD-1 blockade in MSI-high rectal cancer.

The post The GI Cancer Sessions: Highlights from ASCO GI 2022 appeared first on VJOncology.

Prostate Cancer Highlights from ASCO GU 2022 Feb 25, 2022

Show notes

The ASCO Genitourinary (GU) Cancers Symposium took place on the 17-19^th February 2022, in San Francisco, CA. Leading experts gave updates on trials in prostate cancer, urothelial carcinoma, renal cell carcinoma, and rare GU cancers, as well as discussing hot topics in the field.

In this podcast, we hear from several experts in the field of prostate cancer, as they update us on some of the biggest trials presented at ASCO GU 2022, including PROpel (NCT03732820), MAGNITUDE (NCT03748641), PRESIDE (NCT02288247), and ARASENS (NCT02799602). These four trials are investigating two ‘hot’ areas in prostate cancer research – PARP inhibitors and androgen receptor (AR) antagonists.

The post Prostate Cancer Highlights from ASCO GU 2022 appeared first on VJOncology.

Updates on HER2-positive breast cancer Feb 15, 2022

Show notes

HER2-positive breast cancer accounts for 15-20% of all breast cancer cases. It was associated with a poor prognosis until the approval of trastuzumab, a monoclonal antibody targeting HER2. Since then, the therapeutic landscape for patients with HER2-positive tumors has changed dramatically, with the introduction of other monoclonal antibodies such as pertuzumab, tyrosine kinase inhibitors including lapatinib and neratinib, and the antibody-drug conjugate trastuzumab emtansine (T-DM1). Currently, patients with HER2-positive breast cancer are treated with a taxane plus trastuzumab in the first-line setting and with T-DM1 in second-line. Several treatments are emerging as viable options for the third-line setting and beyond. Nevertheless, recent highly promising data from clinical trials investigating novel triple combinations such as tucatinib+trastuzumab+capecitabine, and trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, has already started reshaping standard of care treatments for HER2-positive breast cancer.

In this exclusive podcast, Rupert Bartsch, MD, of Medical University Vienna, Vienna, Austria, Javier Cortés, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Wolfgang Janni, MD, PhD, of Ulm University, Ulm, Germany, discuss the latest research updates in HER2-positive breast cancer therapy, sharing data from the practice-changing HER2CLIMB (NCT02614794) and DESTINY-Breast03 (NCT03529110) trials.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post Updates on HER2-positive breast cancer appeared first on VJOncology.

BTOG 2022: Highlights in lung cancer Feb 11, 2022

Show notes

For patients with lung cancer, surgical resection is a treatment option and perioperative management is imperative to improve surgical outcomes. Patients undergoing surgery may face a decline in quality of life, especially those who have co-morbidities or are older. Prehabilitation aims to prepare patients mentally and physically before surgery with exercise, nutrition and stress reduction. Whilst an optimal program is still under investigation, initial research has demonstrated the efficacy of prehabilitation, with patients requiring shorter hospital stays and having fewer post-operative complications.

In this podcast, Matthew Evison, MD, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK; Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; and Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK, discuss the most current advances in the field of lung cancer. Topics include prehabilitation in lung cancer care, the process of understanding a next-generation sequencing (NGS) report, and the increasing role of low dose CT scanning. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.

The post BTOG 2022: Highlights in lung cancer appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected